Brockington, A., Wokke, B., Nixon, H., Hartley, J. and Shaw, P.J. (2007) Screening of the transcriptional regulatory regions of vascular endothelial growth factor receptor 2 (VEGFR2) in amyotrophic lateral sclerosis. BMC Medical Genetics, 8 (Art. N). ISSN 1471-2350Full text available as:
Vascular endothelial growth factor (VEGF) has neurotrophic activity which is mediated by its main agonist receptor, VEGFR2. Dysregulation of VEGF causes motor neurone degeneration in a mouse model of amyotrophic lateral sclerosis (ALS), and expression of VEGFR2 is reduced in motor neurones and spinal cord of patients with ALS.
We have screened the promoter region and 4 exonic regions of functional significance of the VEGFR2 gene in a UK population of patients with ALS, for mutations and polymorphisms that may affect expression or function of this VEGF receptor.
No mutations were identified in the VEGFR2 gene. We found no association between polymorphisms in the regulatory regions of the VEGFR2 gene and ALS.
Mechanisms other than genetic variation may downregulate expression or function of the VEGFR2 receptor in patients with ALS.
|Copyright, Publisher and Additional Information:||© 2007 Brockington et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.|
|Institution:||The University of Sheffield|
|Academic Units:||The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Academic Neurology Unit (Sheffield)|
|Depositing User:||Repository Officer|
|Date Deposited:||07 Aug 2007 13:38|
|Last Modified:||06 Jun 2014 01:23|
|Publisher:||BioMed Central Ltd.|